August 2007- Volume 3, Issue 8
August 2007
In this Issue
Global News
Delaying the inevitable?
Delaying the inevitable?
A commonly expressed concern about building new antibiotics on the scaffolds of failing first-generation compounds is that the new drugs typically target the same molecular pathways as the originals and therefore microbes resistant to the old compound will rapidly become resistant to the new ones.
Decorating old drugs to combat resistance
Decorating old drugs to combat resistance
In a recent issue of the Journal of the American Chemical Society, researchers at the University of Wisconsin-Madison and Milwaukee’s Medical College of Wisconsin described their efforts to bring new life to old antibiotics that are quickly being made obsolete by multidrug-resistant microbes.
Amgen, Daiichi Sankyo reach deal on bone antibody
Amgen, Daiichi Sankyo reach deal on bone antibody
Amgen and Daiichi Sankyo Co. Ltd. have announced a collaboration and license agreement for the development and commercialization of denosumab in Japan.
Opening the coffers
Opening the coffers
Congress moves toward increasing funding for FDA’s drug efforts
Informatics
Giving it away for free
Giving it away for free
NimbleGen to distribute DNASTAR software
Adapt or die
Adapt or die
Cytel and Tourtellotte bring more predictability to adaptive trials
Planning ahead
Planning ahead
New software technologies help Parexel team enhance clinical trial recruitment and execution
Staying on the alert
Staying on the alert
Sentrx adds Clintrace pharmacovigilance product to its lineup
Research & Development
Broad cancer collaboration
Broad cancer collaboration
Merck shells out $75 million upfront to co-develop Ariad’s mTOR inhibitor for multiple cancer indications
CHF cohorts
CHF cohorts
Biogen Idec, Cardiokine to co-develop a new drug for treating congestive heart failure
Merck pumps up pipeline
Merck pumps up pipeline
Will purchase NovaCardia for $350 million in stock
A new hope for pain
A new hope for pain
Tikvah, Apkarian strike licensing agreement for chronic pain treatments
Editor's Focus
Emptying the drawer of the editorial mind
Emptying the drawer of the editorial mind
Here are a few thoughts that rattled around in my mind as I walked the floor of this year’s Drug Discovery and Development of Innovative Therapeutics (DDT) show and conference in Boston recently
Automation & Instrumentation
Go with the flow
Go with the flow
Thar Instruments acquires Berger SFC from Mettler Toledo
Assay assistants
Assay assistants
Nanostream creates new division to create customized assays
Illumina is striking a vein
Illumina is striking a vein
Illumina to help consortium illuminate genetic causes of vascular disease
Turbocharging drug production
Turbocharging drug production
Xcellerex works to speed up protein and vaccine manufacturing
Genomics & Proteomics
Jumping into the RNA fray
Jumping into the RNA fray
Deal with Silence Therapeutics gives AstraZeneca a good foot forward in siRNA research
Divining origins of diabetes
Divining origins of diabetes
Researchers identify new gene for type 1 diabetes
